UPDATE : Wednesday, July 15, 2020
HOME Pharma
Pharmbio launched CINV treatment
  • By Lee Han-soo
  • Published 2018.07.17 14:02
  • Updated 2018.07.17 14:02
  • comments 0

Pharmbio Korea said Tuesday that it has released a prefilled syringe version of Pharmsetron, a treatment for chemotherapy-induced nausea and vomiting (CINV).

Palonosetron, a major component of Pharmsetron, is a second-generation 5-HT3 (serotonin 3 receptor) antiseptic component approved by the U.S. Food and Drug Administration (FDA). It has a long half-life and high receptor binding capacity when compared with the first generation products.

The treatment is effective in both CINV and vomiting and nausea caused by major surgery.

The prefilled syringe formulation improves convenience and allows precise dose administration. It also can prevent infections that may occur during injection preparation, thereby minimizing the infection problem in the hospital.

“We expect that our treatment will help medical staff seeking convenience and safety at a time when the problem of the reusing syringes has become a social issue,” said Woo Dong-wan, managing director of Pharmbio Korea’s marketing department.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top